Skip to main content

Advertisement

SpringerLink
Log in

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called “false” neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wafelman AR, et al. Radio-iodinated MIBG: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.

    Article  CAS  PubMed  Google Scholar 

  2. Weiland DM, Wu J, Brown LE, Manger TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I meta-iodobenzylguanidine. J Nucl Med 1980;21:349-53.

    Google Scholar 

  3. Beierwaltes WH. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives. Med Pediatr Oncol 1987;15:188-91.

    Article  CAS  PubMed  Google Scholar 

  4. Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 1995;22(10):1180-3 (Oct).

    Article  CAS  PubMed  Google Scholar 

  5. Hoefnagel CA, Lewington VJ. MIBG therapy. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. vol 2. 2nd ed. New York: Churchill Livingstone; 1998. p. 1067-81.

    Google Scholar 

  6. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-MIBG. Cancer 2003;97(5):1332-8 (Mar 1).

    Article  CAS  PubMed  Google Scholar 

  7. Radiation Protection, European Commission. Radiation protection following iodine-131 therapy (Exposures due to outpatients or discharged inpatients). Radiation Protection 97.

  8. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of I-131-MIBG therapy FOR in the treatment of children with stage 4 neuroblastoma? Nuklearmedizin 2006;45(4):145-51.

    CAS  PubMed  Google Scholar 

  9. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.

    Article  CAS  PubMed  Google Scholar 

  10. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25(9):1054-60 Mar 20.

    Article  CAS  PubMed  Google Scholar 

  11. Royal HD, Pierson JR, Fletcher JW, et al. Procedure guideline for guideline development. J Nucl Med 1996;37:878-81.

    CAS  PubMed  Google Scholar 

  12. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller ST, Kemshead JT, et al. Phase I/II study of iodine-131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol 1992;10:1889-96.

    Article  CAS  PubMed  Google Scholar 

  13. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumour and whole-body dosimetry with tumour response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42(11):1713-21. Nov.

    CAS  PubMed  Google Scholar 

  14. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20(2):195-9.

    Article  CAS  PubMed  Google Scholar 

  15. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-MIBG therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 2003;25(7):543-7 (Jul).

    Article  PubMed  Google Scholar 

  16. Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA. Patient dosimetry after I-131-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun 2001;22(4):367-74.

    Article  CAS  PubMed  Google Scholar 

  17. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47(17):3211-23.

    Article  PubMed  Google Scholar 

  18. Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18(1):81-7.

    Article  CAS  PubMed  Google Scholar 

  19. Fielding SL, Flower MA, et al. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308-16.

    Article  CAS  PubMed  Google Scholar 

  20. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, et al. Dosimetry for fractionated I131-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 2007;22(1):105-12.

    Article  CAS  PubMed  Google Scholar 

  21. Chittenden S, Pratt B, Pomeroy K, Black P, Long C, Smith N, et al. Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm 2007;22(2):247-53.

    Article  Google Scholar 

  22. MIRD Committee of Society of Nuclear Medicine. MIRD Dose Estimate Report No. 5. J Nucl Med 1975;16:587.

    Google Scholar 

  23. International Committee on Radiological Protection, ICRP Publication 53, Radiation dose to patients from radiopharmaceuticals, Annals of the ICRP, 18, 1-4 (1987).

    Article  Google Scholar 

  24. International Committee on Radiological Protection, ICRP Publication 60, Recommendations of the International Commission on Radiological Protection, Annals of the ICRP, 21, 1-3 (1991).

    Article  Google Scholar 

Download references

Disclaimer

This guideline summarises the views of the Therapy Committee of the EANM and reflects recommendations for which the EANM cannot be held responsible.

The guidelines have been brought to the attention of the National Societies of Nuclear Medicine.

The European Association of Nuclear Medicine has approved guidelines to promote the cost-effective use of high-quality nuclear medicine procedures. These generic recommendations cannot be rigidly applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures or exclusive of other procedures reasonably directed to obtaining the same results. Advances in medicine occur at a rapid rate. The date of a guideline should always be considered in determining its current applicability.

The recommendations should be taken in the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.

Last amended: December 2007.

Author information

Authors and Affiliations

  1. CH Lyon Sud, EA 3738, HCL, UCBL, 165 Chemin du Grand Revoyet, 69495, Pierre Benite Cedex, France

    Francesco Giammarile

  2. U.O. di Medicina Nucleare, Istituto Clinico Humanitas, via Manzoni, 56, 20089, Rozzano (MI), Italy

    Arturo Chiti

  3. Klinik und Poliklinik für Nuklearmedizin, Universität Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

    Michael Lassmann

  4. Department of Nuclear Medicine, University Medical Center Maastricht, P. Debyelaan 25, Postbox 5800, 6202 AZ, Maastricht, The Netherlands

    Boudewijn Brans

  5. Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK

    Glenn Flux

Authors
  1. Francesco Giammarile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arturo Chiti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Lassmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Boudewijn Brans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Glenn Flux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Giammarile.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giammarile, F., Chiti, A., Lassmann, M. et al. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35, 1039–1047 (2008). https://doi.org/10.1007/s00259-008-0715-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-0715-3

Keywords

Search

Navigation